Phocas Financial’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-46,170
Closed -$3.77M – 109
2026
Q2
$3.77M Buy
46,170
+26,295
+132% +$1.9M 0.52% 82
2026
Q1
$1.35M Sell
19,875
-5,607
-22% -$397K 0.21% 121
2025
Q4
$1.94M Sell
25,482
-11,752
-32% -$854K 0.25% 114
2025
Q3
$2.29M Buy
+37,234
New +$1.94M 0.3% 106
2023
Q4
– Sell
-64,701
Closed -$1.45M – 184
2023
Q3
$1.45M Sell
64,701
-15,996
-20% -$595K 0.21% 118
2023
Q2
$3.28M Sell
80,697
-21,203
-21% -$1.04M 0.45% 92
2023
Q1
$4.94M Buy
101,900
+32,035
+46% +$1.46M 0.71% 60
2022
Q4
$2.67M Sell
69,865
-71
-0.1% -$2.95K 0.38% 101
2022
Q3
$3.51M Buy
+69,936
New +$3.43M 0.54% 82

Other funds holding PTCT

Phocas Financial's PTCT Position: Q3 2026 in Review

Phocas Financial sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 46,170 shares — an estimated $3.77M sold.

Phocas Financial first reported a position in PTCT in Q3 2022 and held it in 9 quarters. The position peaked at $4.94M in Q1 2023. 275 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Phocas Financial reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Phocas Financial sold 46,170 PTC Therapeutics shares in Q3 2026, an estimated $3.77M.
  • Phocas Financial first reported a position in PTC Therapeutics in Q3 2022 and held it in 9 quarters.
  • Phocas Financial's PTC Therapeutics position peaked at $4.94M in Q1 2023.
  • 275 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Phocas Financial's 13F filing for Q3 2026.